2024
Meningeal lymphatic vessel dysfunction driven by CGRP signaling causes migraine-like pain in mice
Thomas J, Schindler E, Gottschalk C. Meningeal lymphatic vessel dysfunction driven by CGRP signaling causes migraine-like pain in mice. Journal Of Clinical Investigation 2024, 134: e182556. PMID: 39087472, PMCID: PMC11290958, DOI: 10.1172/jci182556.Peer-Reviewed Original ResearchConceptsBlocking CGRP signalingCGRP receptor componentsMigraine-like painCervical lymph nodesGap junction proteinPrimary headache disordersLymphatic vessel dysfunctionAcute migrainePharmacological blockadeLymph nodesHeadache disordersNeurological symptomsJunction proteinsCGRPLymphatic vesselsMeningeal lymphatic vesselsInducible knockoutVessel dysfunctionMigraineReceptor componentsHeadachePainPathophysiologyDysfunctionMicePsilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial
Schindler E, Sewell R, Gottschalk C, Flynn L, Zhu Y, Pittman B, Cozzi N, D'Souza D. Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. Journal Of The Neurological Sciences 2024, 460: 122993. PMID: 38581739, DOI: 10.1016/j.jns.2024.122993.Peer-Reviewed Original ResearchConceptsAttack frequencyCluster headacheCluster headache attack frequencyExtension phaseEffects of repeated treatmentReduction of attack frequencyPlacebo-controlled studyHeadache attack frequencyAdministration of psilocybinRandomized controlled trialsDouble-blindPsilocybin administrationPulse regimenAdverse eventsPulse regimensHeadache diaryTherapeutic efficacyDrug sessionsPulse administrationHeadacheStudy participantsWeeks
2022
Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial
Schindler E, Sewell R, Gottschalk C, Luddy C, Flynn L, Zhu Y, Lindsey H, Pittman B, Cozzi N, D'Souza D. Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial. Headache The Journal Of Head And Face Pain 2022, 62: 1383-1394. PMID: 36416492, DOI: 10.1111/head.14420.Peer-Reviewed Original ResearchConceptsAttacks/weekPulse regimenCluster headachePsychotropic effectsAttack frequencyPlacebo-controlled studyPlacebo-controlled trialSerious adverse eventsEffects of psilocybinEffect sizeChronic participantsEfficacy outcomesAdverse eventsModerate effect sizeHeadache burdenHeadache disordersTherapeutic effectHeadache diaryPsilocybin administrationDrug sessionsExperimental drugsRegimenPsilocybin-containing mushroomsDefinitive studiesFinal analysisMigraine—Not Just a Numbers Game
Kopel D, Gottschalk C. Migraine—Not Just a Numbers Game. Neurology 2022, 100: 357-358. PMID: 36396450, DOI: 10.1212/wnl.0000000000201566.Peer-Reviewed Original ResearchConceptsPatient-reported outcome measuresSide effectsAbortive medication useMigraine-related qualityQuality of lifePrimary endpointPreventive therapyMedication useHeadache daysMigraine treatmentPatient populationTreatment optionsPreventive treatmentRecent trialsMigraine pathophysiologyNeurologic disordersDrug trialsOutcome measuresPatient confidenceMost headachesPrescription choicesClinical practicePatientsTherapyMore yearsThe Epidemiology of Primary Headache Disorders
Kopel D, Gottschalk C. The Epidemiology of Primary Headache Disorders. Seminars In Neurology 2022, 42: 449-458. PMID: 36104164, DOI: 10.1055/a-1942-6823.Peer-Reviewed Original ResearchConceptsPrimary headache disordersHeadache disordersCommon primary headache disorderHigher migraine prevalenceNumber 1 causeCommon headache disorderCause of disabilityBurden of migrainePopulation-based estimatesTension-type headacheAmerican Indian/Alaskan NativeAI/AN menChronic migrainePrevalence of stigmaMigraine prevalenceGlobal burdenClinical careEpidemiologic studiesMigraine incidenceMigrainePrevalence estimatesDisease StudyPrevalenceAlaskan NativesDisorders
2020
Characterizing the providers of and reimbursement for chronic migraine chemodenervation among the Medicare population
Torabi SJ, Kasle DA, Savoca EL, Gottschalk CH, Manes RP. Characterizing the providers of and reimbursement for chronic migraine chemodenervation among the Medicare population. Headache The Journal Of Head And Face Pain 2020, 61: 373-384. PMID: 33337542, DOI: 10.1111/head.14040.Peer-Reviewed Original ResearchConceptsAdvanced practice providersHigh-volume providersMedicare populationTreatment modalitiesMedicare patientsPractice providersSubstantial geographic variationMedicare Provider UtilizationProcedure volumeCPT codesPopular treatmentHigher mean numberNeurologistsCross-sectional dataProvider UtilizationMean numberPhysiciansSubstantial proportionChemodenervationReimbursement trendsTreatmentTotal beneficiariesProvidersTotalTotal numberExploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D'Souza D. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics 2020, 18: 534-543. PMID: 33184743, PMCID: PMC8116458, DOI: 10.1007/s13311-020-00962-y.Peer-Reviewed Original ResearchConceptsTherapeutic effectAdverse eventsSingle administrationPsychotropic effectsWeekly migraine daysSerious adverse eventsCross-over studyEffects of psilocybinOral placeboMigraine daysMigraine frequencyClinical effectsControlled StudyHeadache disordersMigraine headacheHeadache diaryDrug effectsDrug AdministrationNeuropsychiatric conditionsMigraineFinal analysisStudy proceduresReceptor ligandsWeeksAdministrationEptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing
Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S. Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. Headache The Journal Of Head And Face Pain 2020, 60: 2220-2231. PMID: 33165938, PMCID: PMC7756794, DOI: 10.1111/head.14007.Peer-Reviewed Original ResearchConceptsEptinezumab 100Days/monthDay 1Chronic migrainePreventive efficacyCalcitonin gene-related peptideMonthly migraine daysPercentage of patientsPrevention of migraineGene-related peptideTreatment effectsMigraine preventive effectMigraine daysInitial dosePreventive effectEptinezumabWeek 1MigrainePatientsPlaceboSustained preventionMonoclonal antibodiesEfficacyMonthsNonsignificant results
2019
Cognitive Biases & Errors in Headache Medicine
Gottschalk CH. Cognitive Biases & Errors in Headache Medicine. Headache The Journal Of Head And Face Pain 2019, 59: 1863-1870. PMID: 31680238, DOI: 10.1111/head.13686.Peer-Reviewed Original Research
2015
Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey
Schindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey. Journal Of Psychoactive Drugs 2015, 47: 372-381. PMID: 26595349, DOI: 10.1080/02791072.2015.1107664.Peer-Reviewed Original ResearchConceptsCluster headacheIndoleamine hallucinogensConventional medicationsChronic cluster headachePain syndromePreventative medicationsAlternative medicationsLysergic acid diethylamideHeadache clinicConventional therapyCluster periodHeadacheMedicationsFinal analysisAcid diethylamideHallucinogensFurther investigationMost responsesSignificant numberAdditional evidenceParticipantsRemissionPatientsSyndromeClinicTreatment of Chronic Migraine with Focus on Botulinum Neurotoxins
Schaefer SM, Gottschalk CH, Jabbari B. Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins. Toxins 2015, 7: 2615-2628. PMID: 26184313, PMCID: PMC4516932, DOI: 10.3390/toxins7072615.Peer-Reviewed Original ResearchConceptsChronic migraineBotulinum toxin injection therapyLarge healthcare costsBotulinum toxin therapyTreatment of migraineCommon neurological disorderToxin therapyInjection therapyPathophysiological mechanismsMigraine pathophysiologyHealthcare costsMigraineNeurological disordersAnimal dataBotulinum neurotoxinTherapyTreatmentInjection techniqueCurrent understandingMedicationsPathophysiology
2005
Cortical γ-Aminobutyric Acid Type A–Benzodiazepine Receptors in Recovery From Alcohol Dependence: Relationship to Features of Alcohol Dependence and Cigarette Smoking
Staley JK, Gottschalk C, Petrakis IL, Gueorguieva R, O’Malley S, Baldwin R, Jatlow P, Verhoeff NP, Perry E, Weinzimmer D, Frohlich E, Ruff E, van Dyck CH, Seibyl JP, Innis RB, Krystal JH. Cortical γ-Aminobutyric Acid Type A–Benzodiazepine Receptors in Recovery From Alcohol Dependence: Relationship to Features of Alcohol Dependence and Cigarette Smoking. JAMA Psychiatry 2005, 62: 877-888. PMID: 16061765, DOI: 10.1001/archpsyc.62.8.877.Peer-Reviewed Original ResearchConceptsWeeks of abstinenceIomazenil single-photon emissionSingle photon emissionDays of sobrietyAlcohol dependenceIomazenil uptakeTomographic scanBenzodiazepine receptorsVoxel-based statistical parametric mappingReceptor adaptationDistribution volumeReceptor functionGamma-aminobutyric acid type ABenzodiazepine receptor levelsIodine I 123Reduced receptor functionHuman alcohol dependenceLast alcoholic drinkHealthy comparison groupStatistical parametric mappingAlcohol withdrawalClinical featuresSmoking statusCigarette smokingAcute withdrawal
2001
Cognitive Function and Cerebral Perfusion During Cocaine Abstinence
Gottschalk C, Beauvais J, Hart R, Kosten T. Cognitive Function and Cerebral Perfusion During Cocaine Abstinence. American Journal Of Psychiatry 2001, 158: 540-545. PMID: 11282686, DOI: 10.1176/appi.ajp.158.4.540.Peer-Reviewed Original ResearchQuantitative medial temporal lobe brain morphology and hypothalamic-pituitary-adrenal axis function in cocaine dependence: a preliminary report
Jacobsen L, Giedd J, Kreek M, Gottschalk C, Kosten T. Quantitative medial temporal lobe brain morphology and hypothalamic-pituitary-adrenal axis function in cocaine dependence: a preliminary report. Drug And Alcohol Dependence 2001, 62: 49-56. PMID: 11173167, DOI: 10.1016/s0376-8716(00)00159-9.Peer-Reviewed Original ResearchConceptsTotal brain volumeAdrenocorticotropin hormoneMagnetic resonance imagingCocaine dependenceHealthy subjectsHippocampal damageBrain volumeCortisol levelsAdrenal axis functionChronic cocaine dependenceCocaine-dependent subjectsCocaine-dependent patientsDays of abstinenceDirect toxic effectMedial temporal lobeAxis functionChronic elevationDependent patientsClinical studiesHippocampal neuronsTemporal lobeOvine corticotropinPlasma cortisolResonance imagingDependent subjectsFunctional Magnetic Resonance Imaging of Cocaine Craving
Wexler BE, Gottschalk CH, Fulbright RK, Prohovnik I, Lacadie CM, Rounsaville BJ, Gore JC. Functional Magnetic Resonance Imaging of Cocaine Craving. American Journal Of Psychiatry 2001, 158: 86-95. PMID: 11136638, DOI: 10.1176/appi.ajp.158.1.86.Peer-Reviewed Original ResearchConceptsFunctional magnetic resonance imagingHealthy subjectsCocaine-dependent subjectsMagnetic resonance imagingResonance imagingCocaine addictsReported onsetBrain activationBrain activityRegional brain activationFrontal lobe activationAnterior cingulate activationNeurobiology of addictionCocaine cravingAnterior cingulatePatientsFrontal lobePhysiologic linkSensory areasComparison of groupsDrug cravingDysphoric statesLess activationGeneral abnormalityCingulate activation